Five things for pharma marketers to know: Thursday, May 12, 2016

1. Valeant Pharmaceuticals has not followed through on its public promise to provide hospitals with discounts on two heart drugs. The company's new CEO, Joseph Papa, said Valeant is working to resolve the issue. (NYT)

2. AstraZeneca's experimental drug, selumetinib, received orphan-drug status as a treatment for a type of thyroid cancer. The drug had failed in trials as a therapy for a rare eye cancer. (Reuters)

3. Allergan promoted Bill Meury to chief commercial officer and Bob Stewart to chief operating officer as part of a reorganization. Allergan reworked its strategy after a proposed merger with Pfizer fell through. (WSJ, MM&M)

4. Some patients who participate in clinical trials are called “exceptional responders,” and researchers are beginning to study the phenomenon. (NYT)

5. A judge ordered that files about the marketing of Purdue Pharma's painkiller OxyContin will be unsealed after Stat, a news site, filed a motion. (Stat)